| Type 2 Diabetes Mellitus |
1 |
1 |
| Cardiovascular Risk Management |
0 |
0.87 |
| Coronary Artery Disease (CAD) |
0 |
0.7 |
| Cardiovascular disease |
0 |
0.66 |
| Hypertension |
0 |
0.57 |
| Heart Failure (HF) |
0 |
0.55 |
| Clinical Guidelines |
0 |
0.41 |
| Endocrinology |
0 |
0.25 |
| Heart |
0 |
0.25 |
| Primary Care |
0 |
0.25 |
| Angiotensin II Receptor Blockade |
0 |
0.17 |
| Hospital |
0 |
0.17 |
| Metabolism |
0 |
0.17 |
| Receptors |
0 |
0.17 |
| SGLT2 Inhibitor |
0 |
0.17 |
| Chronic Kidney Disease |
0 |
0.12 |
| Renal Disease |
0 |
0.12 |
| Renal Failure |
0 |
0.12 |
| ACE Inhibitor |
0 |
0.08 |
| Adherence |
0 |
0.08 |
| Anticoagulation Therapy |
0 |
0.08 |
| Board Certification |
0 |
0.08 |
| Colorado |
0 |
0.08 |
| Grant |
0 |
0.08 |
| Infarction |
0 |
0.08 |
| Interprofessional Continuing Education |
0 |
0.08 |
| Kidney |
0 |
0.08 |
| Other Specialty |
0 |
0.08 |
| Percutaneous Coronary Intervention |
0 |
0.08 |
| Professional Societies |
0 |
0.08 |
| Statins |
0 |
0.08 |
| Texas |
0 |
0.08 |
| Lipids Management |
0 |
0.07 |
| Myocardial Infarction (MI) |
0 |
0.07 |